Aquinox in comparison to industry ETF
The iShares Nasdaq Biotechnology ETF (IBB) has performed quite well with a PE (price-to-earnings) ratio of 85.21x and has given year-to-date net asset value of 22.46%, which is quite close to the NASDAQ Biotechnology Index of 22.73%.
In comparison with Aquinox, the iShares Nasdaq Biotechnology has outperformed the stock with an 8% rise in the price in 2Q15. Aquinox has fallen down by 16% in the same quarter. The company is still in the development stage, so it doesn’t yet have a PE ratio.
An analysis of Aquinox’s performance
Aquinox Pharmaceuticals’ (AQXP) competitors include Trillium Therapeutics (TRIL)(TRIL), Astellas Pharma (ALPMY), GlaxoSmithKline (GSK), Pfizer (PFE), Novartis (NVS), AstraZeneca (AZN), and Meda AB (MDABY).
We can compare Aquinox’s performance with Trillium (TRIL)(TRIL) and Astellas Pharma (ALPMY), as both these companies have negative EPS (earnings per share) and are in the growing stage. At the same time, Pfizer and GlaxoSmithKline have PEs of 24.1x and 7.16x, respectively. Both these companies are large-cap companies and have positive results due to a large number of products.
On the overall industry side, the company can increase their PE and EPS by achieving their break-even level, which also helps the company in expanding itself and increasing its profit. Aquinox has a positive future outlook and will likely continue to better its performance in the near future.